SILVER SPRING, Md. - An FDA panel of outside experts Tuesday in a unanimous vote said regulators should allow makers of generic versions of vancomycin to use in vitro dissolution testing alone to demonstrate bioequivalence for products containing the same ingredients in the same amounts as ViroPharma Inc.'s Vancocin. (BioWorld Today)

Biotech start-up Avila Therapeutics Inc. not only raised $30 million in a Series B financing, but snagged a deal potentially worth $200 million in up-front and milestones plus royalties with Novartis Option Fund. (BioWorld Today)